Clinical trials: Immunity to Influenza Vaccine
Influenza, Vaccine Virus Shedding
Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune) is the standard influenza vaccine given to children aged 2-17 years of age in the UK.
- Trial name
- Flu-M3 (NCT04110366)
- Testing
- Live attenuated influenza vaccine, Vehicle control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Fever
Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV
The study team aims to conduct a double-blind, placebo-controlled, pilot study to assess the effect of prophylactic antipyretics on the immune responses and rates of fever after inactivated influenza vaccine (IIV) in children 12…
- Trial name
- NCT01946594
- Testing
- Acetaminophen
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Duke University
Immune Response
Evaluation of the Effect of a Soluble Fiber Consumption on Immunity Response
At European level, the European Food Safety Agency has recognized two claims relating to the effects of prebiotics on the gastrointestinal sphere and on the immune system.
- Trial name
- NUTIVAC (NCT05313451)
- Testing
- Soluble fiber
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- CEN Biotech
Healthy Aging
Beta-glucan and Immune Response to Influenza Vaccine
This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.
- Trial name
- M-Unity (NCT05074303)
- Testing
- Influenza Vaccine, Beta-glucan
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Florida
Dengue, Sepsis
Immune Responses to Dengue and Sepsis
The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, influenza…
- Conditions
- Dengue, Sepsis, Influenza
- Trial name
- DEN-SEP (NCT07040202)
- Where
- 4 sites in Cambodia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Influenza, Influenza Immunisation
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
This was a Phase IV open label and single arm study, with the aim of enrolling up to 55 healthy males and non-pregnant females in a single site, age 18-49 years old, inclusive.
- Trial name
- NCT02485639
- Testing
- Influenza Virus Vaccine Inactivated
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Optimizing Influenza Vaccination in Surgical Oncology Patients
Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu.
- Trial name
- NCT01698177
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Stony Brook University
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the seasonal quadrivalent influenza vaccine (FLU-QIV) in adults aged 60…
- Trial name
- NCT04841577
- Testing
- RSVPreF3 OA investigational vaccine, FLU-QIV
- Where
- 14 sites in New Zealand, Panama and 1 more
- Volunteers
- 976 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluating Immune Response to Seasonal FluMist in Healthy Adults
The Live-Attenuated Influenza Vaccine (LAIV), also known as FluMist, has been shown to be effective in children but less effective in adults.
- Trial name
- NCT01673425
- Testing
- Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- National Center for Occupational Health and Infection Control
Influenza
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults
Background: Influenza (flu) virus causes 3 to 5 million cases of severe illness and up to 650,000 deaths per year worldwide. Current vaccines work well against single strains of flu virus.
- Trial name
- NCT05968989
- Testing
- VRC-FLUMOS0116-00-VP( FLUMos-v2)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, H1N1 Influenza Virus
Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women
Both pregnant women and people infected with HIV are at increased risk of viral infection, including influenza infection. Pregnant women infected with HIV may be at particular risk of infection from the new H1N1 influenza virus.
- Trial name
- NCT00992017
- Testing
- Influenza A (H1N1) monovalent vaccine
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65…
- Trial name
- NCT05559476
- Testing
- RSVPreF3 OA investigational vaccine, FLU HD vaccine
- Where
- 46 sites in United States
- Volunteers
- 1,029 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Training Study to Characterize Biomarkers to Flu Vaccines
It is thought that vaccines trigger innate inflammatory responses to induce antigen-specific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side…
- Trial name
- NCT01771367
- Testing
- Fluad, Agrippal
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Grippe, Influenza
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza.
- Conditions
- Grippe, Influenza, Vaccines
- Trial name
- NCT06179446
- Testing
- pdmFlu vaccine, Licensed influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
The purpose of the study is to investigate and compare the human immune response in epithelial cells of the nasopharyngeal mucosa and in blood to live, attenuated influenza vaccine (LAIV) in adults and in children.
- Trial name
- NCT03023683
- Testing
- FluMist®
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older
The purpose of this clinical study was to evaluate immune responses measuring antibodies in serum and secretions and cellular immune responses generated by CAIV-T vaccine in healthy adults aged 18 years and older as a means to…
- Trial name
- NCT00192153
- Testing
- CAIV-T or TIV
- Where
- 2 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Human
A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA.
- Trial name
- NCT07851246
- Testing
- mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2
- Where
- 12 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Herpes Zoster
Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
Vaccines are used to prevent infectious diseases worldwide. Unfortunately, many vaccines, like the flu vaccine, are less effective in older adults.
- Trial name
- NCT05082688
- Testing
- Herpes zoster vaccination (Shingrix, GSK), Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)
- Where
- Netherlands
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Influenza
Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine
This study may determine whether laboratory studies of people's blood cells, who have received vaccines against H5 influenza, or "bird flu," will help to decide if the vaccines are going to be prevent disease effectively.
- Trial name
- NCT00311727
- Testing
- Influenza A/H5N1
- Where
- 3 sites in United States
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over
The goal of this study is to determine whether the immune responses induced by Fluviral, the investigational vaccine, are comparable to those induced by Fluzone, which is an influenza vaccine currently licensed in the U.S.
- Trial name
- NCT00232947
- Testing
- Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone)
- Where
- 10 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- ID Biomedical Corporation, Quebec